Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.

ABSTRACT:

Introduction

This study examined the association between metformin-based oral antihyperglycemic combination therapy and the risk of developing dementia in patients with newly diagnosed type 2 diabetes mellitus (T2DM).

Methods

We conducted a retrospective cohort study using data from a random sample of 2,000,000 individuals in Taiwan's National Health Insurance Research Database from 2000 to 2018. A total of 44,073 patients with newly diagnosed T2DM were identified and categorized into four groups based on initial treatment: metformin (MET)-sulfonylureas (SU), MET-dipeptidyl peptidase-4 inhibitor (DPP4i), MET-thiazolidinedione (TZD), and MET-glinides. The participants were followed until December 2018.

Results

The hazard ratio of MET-TZD was 0.73 (95% confidence interv

SUBMITTER: Hsieh TC 

PROVIDER: S-EPMC12358239 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature